Apoptosis is accompanied by the activation of a number of apoptotic proteases (caspases) which selectively cleave speci®c cellular substrates. Caspases themselves are zymogens which are activated by proteolysis. It is widely believed that`initiator' caspases are recruited to and activated within apoptotic signalling complexes, and then cleave and activate downstream`eector' caspases. While activation of the eector caspase, caspase-3, has indeed been observed as distal to activation of several dierent initiator caspases, evidence for a further downstream proteolytic cascade is limited. In particular, there is little evidence that cellular levels of caspase-3 that are activated via one pathway are sucient to cleave and activate other initiator caspases. To address this issue, the ability of caspase-3, activated upon addition to cytosolic extracts of cytochrome c, to cause cleavage of caspase-2 was investigated. It was demonstrated that cleavage of caspase-2 follows, and is dependent upon, activation of caspase-3. Moreover, the activation of both caspases was inhibited by Bcl-2. Together, these data indicate that Bcl-2 can protect cells from apoptosis by acting at a point downstream from release of mitochondrial cytochrome c, thereby preventing a caspase-3 dependent proteolytic cascade.
Introduction
Apoptosis is a form of cell death activated by the induction of cellular suicide pathways in response to a variety of stimuli. Recent advances have led to a widely accepted model, whereby many of the morphological features of apoptotic cells are a consequence of the action of a conserved family of cysteine proteases (caspases) on speci®c cellular substrates (Nicholson et al., 1995) . Caspases themselves are present as proenzymes that are readily cleaved and activated during apoptosis, providing the cell with a means to rapidly amplify its apoptotic response [see Cohen (1997) for review]. In addition, the broadly similar patterns of protein cleavage and consequent morphological changes that occur during apoptosis, irrespective of the stimulus, are consistent with activation of a proteolytic cascade. Evidence for such a cascade has come from examination of apoptotic cells and biochemical studies. Firstly, induction of apoptosis is accompanied by the activation of several caspases within the same cell (Faleiro et al., 1997; Polverino and Patterson, 1997) . Secondly, evidence from the differential timing of caspase activation after addition of apoptotic stimuli are consistent with a hierarchy of caspase activities (Faleiro et al., 1997; Li et al., 1997a; Takahashi et al., 1997) . In vitro studies are also consistent with a caspase cascade, since puri®ed recombinant caspases will cleave each other eectively [see Cohen (1997) ]. However, the relevance of these studies to activation of caspases in vivo are problematic, since the concentrations of caspases and incubation conditions may not be physiological. Moreover, additional caspase substrates, and factors that might regulate the speci®city of caspase action, are absent from such studies. Although several recent studies have avoided some of these diculties by adding exogenously-activated caspases to naive extracts (Martin et al., 1996; Muzio et al., 1997; Orth et al., 1996) , these still fall short of demonstrating that endogenous levels of caspases are sucient to drive a proteolytic cascade. Evidence for such a dependency when using endogenous proenzymes as the sole source of caspase activity remains limited.
The pathway leading to caspase activation varies according to the apoptotic stimulus, though several features are conserved. Thus, cell death caused by activation of the TNFR-1 or CD95/Fas receptors is brought about by the recruitment of the adaptor protein FADD (Fas-Associated protein with Death Domain) (Chinnaiyan et al., 1995) . In the case of the TNFR-1, FADD recruitment requires prior binding of TRADD (TNFR-1-Associated Death Domain protein) (Hsu et al., 1995) . FADD in turn recruits procaspase-8 via a homophilic interaction between the death eector domains of these proteins, and this event is closely followed by autocatalytic cleavage and activation of the clustered zymogen (Boldin et al., 1996; Yang et al., 1998) . The TNFR-1 receptor can also mediate activation of caspase-2 via the recruitment of a death-inducing signalling complex. In this case RIP (Receptor-Interacting Protein) (Stanger et al., 1995) acts as an adaptor for the recruitment of RAIDD (RIP-Associated ICH-1/CED-3-homologous protein with a Death Domain), which subsequently binds to procaspase-2 (Duan and Dixit, 1997) . As for caspase-8, it is believed that caspase-2 will autoactivate when oligomerized (Butt et al., 1998) . In contrast, the activation of caspase-9 by apoptotic stimuli proceeds via recruitment of the zymogen to a signalling complex containing Apaf-1 (Apoptotic protease activating factor-1) and cytochrome c (Li et al., 1997b; Liu et al., 1996; Zou et al., 1997) , which is believed to be released from mitochondria as an early event in several models of apoptosis (Yang et al., 1997) . Based on the ®nding that both caspase-8 (Muzio et al., 1997) and caspase-9 (Li et al., 1997b) will cleave and activate caspase-3 in cell-free assays of apoptosis, it is widely considered that these`initiator' caspases lie at the apex of separate apoptotic cascades that converge upon activation of downstream`eector' caspases.
Though recent work has shed light on the mechanism of the Apaf-1/caspase-9 signalling pathway, several questions remain concerning its role in activation of other caspases. It is possible, for example, that the cytochrome c/Apaf-1 may activate other caspases in addition to caspase-9, particularly those with NH 2 -terminal Caspase Recruitment Domains (CARDs), such as caspase-2. Additionally, caspase-9 itself may activate caspases other than caspase-3. If, however, only caspase-3 is activated via the caspase-9 pathway, it is unclear whether physiological concentrations of caspase-3 are sucient to activate other caspases and consequently generate a downstream cascade. In particular, the extent to which caspase-3 can cleave other initiator caspases and thus lead to Figure 1 Cytochrome c and dATP act synergistically to activate caspase-3. Cytosolic extracts derived from HeLa cells were incubated with the indicated concentrations of cytochrome c in the absence (squares) or presence (diamonds) of 1 mM dATP. At the indicated time samples were assayed for their ability to cleave the¯uorogenic caspase-3 substrate Ac-DEVD-AMC activation of parallel apoptotic cascade(s) is not established.
Of central importance to cell survival is careful regulation of the initiation of the apoptotic cascades. One of the most widely-studied negative regulators of apoptosis is the proto-oncogene Bcl-2. Since activation of caspase-9 is dependent upon cytochrome c (Li et al., 1997b; Liu et al., 1996) , and Bcl-2 is localized to the mitochondrial membrane (Hockenbery et al., 1990) , an attractive hypothesis is that Bcl-2 acts by preventing release of cytochrome c. Indeed, it has been demonstrated that overexpression of Bcl-2 prevents eux of cytochrome c from mitochondria whilst protecting cells from apoptosis (Yang et al., 1997) . More recent reports, however, show that Bcl-2 will protect cells from apoptosis induced either by microinjection of cytochrome c or by Bax-induced release of cytochrome c from mitochondria (RosseÂ et al., 1998; Zhivotovsky et al., 1998) . These experiments suggest that Bcl-2 may have additional downstream eects on the apoptotic pathway over and above that on mitochondrial permeability (see also Reed (1997) ). To address this question, and to understand how the cytochrome c signalling pathway can initiate other caspase cascades, we have examined the regulation of both procaspase-3 and procaspase-2 cleavage in mammalian cytosolic extracts.
Results
Activation of caspase-3 and caspase-2 in cytosolic extracts.
To examine the regulation and downstream eects of caspase-3 activity, we exploited a previously described cell-free system that reconstitutes the activation pathway (Liu et al., 1996) . Consistent with other studies, we found that eective and rapid generation of active caspase-3 required addition of both cytochrome c and dATP ( Figure 1 ). However, we observed that the need for dATP in order to attain ®rst the maximal level, and then the maximal rate of activation, declined with increasing concentration of cytochrome c. At 10 mM cytochrome c, generation of active caspase-3 proceeded with a half-time of approximately 15 min, which was unaected by addition of dATP.
This half-time for caspase-3 activation was consistent with the rate of procaspase-3 cleavage ( Figure 2 , upper panel). Cleavage from the p32 proenzyme to produce the p17 subunit was a two-step process, with initial cleavage to a p20 intermediate. Within 30 min, when the extent of caspase-3 activity is maximal, the p17 form was the major caspase-3 species present. The rate of caspase-2 cleavage was somewhat slower than that of caspase-3, as determined by appearance of the p12 subunit of the active protease (Figure 2 , lower panel). Appearance of the p12 subunit was delayed until a substantial fraction of caspase-3 had been activated.
The data described in Figure 2 suggested that there may be a causal relationship between generation of active caspase-3 and cleavage of caspase-2. To test this further, we examined whether activation of caspase-2 could be prevented by inclusion of the caspase-3 inhibitor Ac-DEVD-CHO. As shown in Figure 3 , cleavage of in vitro-translated procaspase-2 was prevented by Ac-DEVD-CHO at concentrations above 100 nM (essentially identical results were obtained when endogenous caspase-2 was analysed by Western blotting 2 h after addition of cytochrome c; data not shown). Similar concentrations of Ac-DEVD-CHO prevented cleavage of PARP, a known caspase-3 substrate. The two-step activation of caspase-3 itself could be dissected by examining sensitivity to Ac-DEVD-CHO. Thus, initial cleavage to generate the p20 form was inhibited partially only by inclusion of micromolar concentrations of Ac-DEVD-CHO. Pre- Activation of caspase-2 in a cell-free system E Swanton et al sumably, this re¯ects the limited ability of this inhibitor to block caspase-9 activity. In contrast, cleavage of p20 to generate p17 was blocked by approximately 100 nM Ac-DEVD-CHO, indicating that it is probably an autocatalytic event.
The dependence of caspase-2 activation on caspase-3 activity was further demonstrated by following procaspase-2 cleavage in extracts that had been speci®cally depleted of procaspase-3. In these extracts both the rate and extent of procaspase-2 cleavage were severely inhibited compared to control extracts. Partial cleavage of procaspase-2 was observed only 3 ± 4 h after cytochrome c addition (Figure 4a) . The rate and extent of caspase-2 activation, as indicated by appearance of the p12 subunit, could be restored to control levels by addition of active recombinant caspase-3 (Figure 4b ). In this experiment, the amount of added caspase-3 activity was carefully titred to ensure that it was the same as that present in control apoptotic extracts (data not shown). Generation of the active form of caspase-2 could also be restored to its normal rate by re-addition of the bound fraction from the immunodepletion experiment (data not shown).
Activation of both proenzymes is regulated by Bcl-2
The above data together suggest that caspase-2 can not be activated directly by caspase-9, or other downstream eectors of cytochrome c, but will be activated in cellular extracts via the action of caspase-3. To further establish that cytochrome c-mediated activation of caspase-2 proceeds via a caspase-9/caspase-3 pathway, Control-(middle panel) or caspase-3-depleted (top panel) extracts were incubated for the indicated times, and the appearance of the p12 subunit of active caspase-2 detected by Western blot. A parallel incubation (bottom panel) contained caspase-3-depleted extract supplemented with recombinant caspase-3 to an activity equivalent to that obtained upon activation of the controldepleted extract Figure 5 Bcl-2 regulates caspase-3 activation in a cytosolic extract. (a) Cytosolic extracts were incubated for 15 min in the presence of the indicated amount of cytochrome c with (diamonds) or without (squares) 400 mg/ml recombinant Bcl-2. Each sample was then assayed for caspase-3 activity. (b) Cytosolic extracts containing 0.5 mM (squares) or 10 mM (diamonds) cytochrome c were incubated for 15 min with the indicated concentration of recombinant Bcl-2. Each sample was then assayed for caspase-3 activity we compared the ability of Bcl-2 to control the activation of both proenzymes. The ability to activate caspase-3 in extracts devoid of mitochondria also gave us the opportunity to determine whether Bcl-2 could regulate caspase activation downstream of cytochrome c release. Generation of active caspase-3 was indeed prevented by a recombinant, soluble form of Bcl-2, in a manner that suggested the ratio of cytochrome c to Bcl-2 was important ( Figure 5) . Firstly, the ability of a single concentration of Bcl-2 to prevent caspase activation could be overcome by adding increased levels of cytochrome c (Figure 5a) . Secondly, the titre of Bcl-2 required to prevent caspase activation varied according to the amount of cytochrome c present in the incubation (Figure 5b ). Consistent with caspase-2 being activated downstream of caspase-3, the rate of activation of both zymogens was substantially reduced by inclusion of Bcl-2 in incubations ( Figure 6 ; note that addition of a lower concentration of cytochrome c led to slower activation of both caspase-3 and caspase-2). Thus, in summary, Bcl-2 prevents activation of caspase-3 in extracts lacking mitochondria, and consequently blocks a pathway leading to activation of a caspase cascade.
Discussion
In this report, we have examined the activation of caspase-3 in cytosolic extracts derived from HeLa cells. We have found, as described by Wang and colleagues (Liu et al., 1996) , that caspase-3 activation requires dATP. In contrast to their study, we found that exogenous cytochrome c was required to obtain ecient caspase-3 activation. This most probably re¯ects a lower concentration of cytochrome c in our extracts, the preparation of which have been optimized to prevent damage to nuclei and thus other organelles (Balch et al., 1984) . Indeed, several extracts were completely unable to activate caspase-3 in the absence of added cytochrome c. This feature enabled us to look more closely at the requirement for both components. Our data indicate that at limiting concentrations of cytochrome c, dATP is essential for ecient activation of caspase-3. Above 2 mM cytochrome c, however, activation proceeds irrespective of addition of dATP (this reaction is presumably driven by endogenous ATP within the extract, since inclusion of an ATP-depleting system inhibited the extent of caspase-3 activation by fourfold; data not shown). Most likely, the anity of Apaf-1 for components of the caspase-9 complex is lower in the presence of ATP compared with dATP. Higher concentrations of other components of the complex would thus be required to drive the reaction forward.
The ®nding that recombinant Bcl-2 could eectively block caspase-3 activation in extracts lacking mitochondria supports previous studies on intact cells, which show that Bcl-2 maintains its anti-apoptotic activity even after generation of a cytoplasmic pool of cytochrome c (RosseÂ et al., 1998; Zhivotovsky et al., 1998) . Essentially similar results have been obtained using Xenopus laevis extracts, suggesting that the mechanism of action of Bcl-2 is conserved (SC, PS, PC; manuscript in preparation). Moreover, we ®nd that the anti-apoptotic activity of Bcl-2 correlates inversely with the concentration of soluble cytochrome c. Thus, it appears likely that Bcl-2 interferes with the generation of an active cytochrome-containing complex by binding cytochrome c, or a downstream eector of cytochrome c. Indeed, recent data indicate that the Bcl-2-related protein Bcl-X L is found in an Apaf-1 and caspase-9-containing complex (Pan et al., 1998b) . The presence of Bcl-2 within a pre-apoptotic signalling complex has been demonstrated previously, since it is found bound to p28/Bap31 and procaspase-8 in an ER-associated complex (Ng et al., 1997) . In this case Bcl-2 is prevented from binding to the complex by its pro-apoptotic relation Bax.
The activation pathway for caspase-3 by caspase-9 is a two-step pathway that can be dissected temporally and by sensitivity to inhibitor, similar to that observed for granzyme B-mediated activation (Martin et al., 1996) . Thus, pro-caspase-3 is cleaved to a p20 form by caspase-9, which is relatively insensitive to Ac-DEVD-CHO. Subsequent cleavage from p20 to p17 is presumably autocatalytic, since it is blocked by Ac-DEVD-CHO at concentrations similar to those that prevent cleavage of the caspase-3 substrate PARP (however, it is formally possible that a caspase with similar sensitivity to Ac-DEVD-CHO as caspase-3 performs the second cleavage event). This order of cleavage suggests that caspase-9 is highly substratespeci®c.
It is possible that the caspase-9/caspase-3 pathway could be utilized during apoptosis to generate other active caspases. In particular, activation of those caspases with long NH 2 -terminal CARDs, which are generally considered`initiator' caspases, would provide the cell with the means to initiate multiple caspase pathways irrespective of the apoptotic stimulus, and thus ensure that a broad range of substrate proteins were cleaved. To date, evidence for such transactivation of caspases has been limited to studies on puri®ed recombinant proteins (Harvey et al., 1996) , or the use of cell-free extracts that have been activated by Figure 6 Bcl-2 regulates caspase-2 and caspase-3 cleavage. Extracts containing 1 mM cytochrome c were incubated for the indicated time without (control) or with (+Bcl-2) 200 mg/ml recombinant Bcl-2, then analysed by Western blot for caspase-3 or caspase-2 cleavage addition of exogenous active caspases (Martin et al., 1996; Muzio et al., 1997; Orth et al., 1996) . The naive extracts used in the present study should contain relative concentrations of dierent caspases similar to those found in vivo, and will therefore provide a more physiological model. Our data indicate that the caspase-9 pathway will indeed lead to activation of other caspase cascades, since procaspase-2 was eciently cleaved. This is in contrast to the report of Pan et al. (Pan et al., 1998a) , who failed to detect cleavage/activation of caspase-2 in cytochrome ctreated extracts. However, activation of caspase-2 did not proceed by caspase-9 dependent cleavage directly, in agreement with Pan et al. (Pan et al., 1998a) and providing further evidence that caspase-9 action is speci®c. Instead, we established by several criteria that activation of caspase-2 required caspase-3 activity. This ®nding extends previous observations by Li et al. (Li et al., 1997a) that caspase-2 is activated in cells by an unde®ned caspase-3-like activity. In conclusion, therefore, we provide evidence that trans-activation between caspase pathways will occur under conditions similar to those found in vivo, but that the ability to transactivate is restricted to a subset of caspases. Presumably, there is limited selective advantage for CARD domain-containing initiator caspases such as caspase-9 to be able to cleave other initiator caspases, since they are likely to be localized away from each other in the cell.
Materials and methods

Reagents
Cytochrome c was obtained from Boehringer Mannheim Ltd., Lewes, Sussex, England. Ac-DEVD-CHO and Ac-DEVD-AMC were bought from Calbiochem-Novabiochem (UK) Ltd. (Nottingham, England) and stored as 10 mM stocks in DMSO at 7208C. Antibodies to caspase-3 (N-19, H-277) and caspase-2 (C-20) were bought from Santa Cruz Inc. (Autogenbioclear, Calne, Wilts, England). HRPconjugated secondary antibodies used for ECL Western blotting were obtained from DAKO. All other reagents were obtained from Sigma Chemicals.
Generation of HeLa extracts
Suspension HeLa cells were grown to a density of 10 6 cells/ ml in MEM modi®ed for suspension cultures (Gibco BRL, Paisley, Scotland) supplemented with 5% foetal calf serum. Cells were harvested from 2 l of culture, washed twice in KEHM buer (50 mM KCl, 10 mM EGTA, 50 mM HEPES, pH 7.4, 2 mM MgOAc) and resuspended in two volumes of the same buer. After addition of DTT (1 mM) and protease inhibitors (1 mg/ml apopain, 1 mg/ml pepstatin A, 5 mg/ml E64, 1 mg/ml chymostatin, 40 mg/ml PMSF from a 10006 stock in DMSO), cells were homogenized by passing through a 8.02 mm bore in a stainless steel block containing a 8.004 mm diameter ball (Balch et al., 1984) . A cytosol fraction was produced by centrifuging the homogenate at 300,000 g for 45 min. The cytosol was snap-frozen and stored at 7808C.
For immunodepletion experiments, cytosol (4 mg protein) was incubated overnight with gentle rotation in a tube containing 40 ml protein A-sepharose beads to which had been pre-bound 8 mg anti-caspase-3 antibody As a control, cytosol was incubated with beads pre-treated with a nonrelevant antibody. Quantitative depletion of procaspase-3 was established by Western blot analysis of serial dilutions of cytosol preparations (data not shown).
To generate apoptotic extracts, a modi®cation to the method of (Liu et al., 1996) was employed. Cytosol (20 mg protein/ml) was normally incubated at 308C with an ATP regenerating cocktail (1 mM ATP, 5 mM creatine phosphate, 10 mg/ml creatine kinase ®nal) and 10 mM cytochrome c. Speci®c times of incubation and alternative additions are detailed in ®gure legends.
Caspase-3 activity assays
Extracts were diluted 20-fold in KEHM buer to arrest the apoptotic programme, and duplicate samples (50 ml) were incubated with 50 mM Ac-DEVD-AMC for 15 min at room temperature (experiments were performed with a recombinant caspase-3 standard to ensure that under these conditions the cleavage of Ac-DEVD-AMC was linear with respect to caspase-3 activity; data not shown). Samples were diluted to 2 ml in water and the generation of¯uorescent product determined.
Recombinant proteins
Recombinant Bcl-2 protein (aa. 1 ± 218 tagged at the Nterminus with hexahistidine) was constructed using standard PCR techniques and cloned into vector ptb375 (Zeneca Pharmaceuticals) for expression in E. coli BL21 cells. Recombinant caspase-3 was produced by expressing the p12 and p17 subunits separately in E. coli BL21 cells. Active enzyme was stored in PBS at 7708C.
[ 35 S]methionine caspase-2 and poly (ADP ribose) polymerase (PARP) were generated by incubating 1 mg of cDNA (cloned into a pcDNA3 vector) with a combined transcription/translation kit (Promega) supplemented with T7 RNA polymerase and 60 mCi [ 
